DDInter1150 DDInter1376
A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Meperidine {u} (Compound) resembles {v} (Compound) Methsuximide
Meperidine {u} (Compound) binds {v} (Gene) SLC6A2
Meperidine {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Meperidine {u} (Compound) causes {v} (Side Effect) Flushing
Meperidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kaolin
Meperidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phentermine
Meperidine {u} may lead to a major life threatening interaction when taken with {v} Granisetron
Meperidine {u} may lead to a major life threatening interaction when taken with {v} Morphine
Meperidine (Compound) resembles Methsuximide (Compound)
Meperidine (Compound) binds SLC6A2 (Gene)
Meperidine (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Meperidine (Compound) causes Flushing (Side Effect)
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine
Meperidine may lead to a major life threatening interaction when taken with Granisetron
Meperidine may lead to a major life threatening interaction when taken with Morphine